Cost-effectiveness of thrombotic thrombocytopenic purpura diagnosis: a retrospective analysis in the University Hospital Center of Lyon (France).
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
pubmed:
17
8
2021
medline:
12
2
2022
entrez:
16
8
2021
Statut:
ppublish
Résumé
The aim of the present study was to perform an economic evaluation of two alternative assays of ADAMTS13 activity (A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats, member 13) for diagnosing thrombotic thrombocytopenic purpura (TTP) in the Hospital of Lyon (France). The study approach was more economic than clinical. We retrospectively calculated the prescription costs of ADAMST13 activity from January to December 2019 for patients depending on the assay: manual ELISA (Technozym) or automated assay (AcuStar Werfen, Instrumentation Laboratory). Then, we compared the cost of therapeutic plasma exchange (TPE) consumption awaiting ADAMTS13 activity assay results. From an economic point of view, the automated assay was more cost-effective. From a clinical one, we supposed that the faster results given by AcuStar could improve patient care by reducing the number of TPEs. Automated assay could improve patient care without increasing costs in our institution.
Identifiants
pubmed: 34393175
doi: 10.1097/MBC.0000000000001071
pii: 00001721-202203000-00005
doi:
Substances chimiques
ADAMTS13 Protein
EC 3.4.24.87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-123Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 2008; 3:249–277.
Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158:323–335.
Maloney N, Martin I, Szczepiorkowski ZM, Dunbar NM. Therapeutic plasma exchange in thrombotic thrombocytopenic purpura. J Clin Apher 2018; 33:436–438.
Coppo P, Cuker A, George JN. Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine. Res Pract Thromb Haemost 2018; 3:26–37.
Sadler JE. Von Willebrand factor, ADAMTS13 and thrombotic thrombocytopenic purpura. Blood 2008; 112:11–18.
Veyradier A, Coppo P. ADAMTS13, von Willebrand factor specific cleaving protease. Med Sci 2011; 27:1097–1105.
Elverdi T, Eskazan AE. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. Drug Des DevelTher 2019; 13:1251–1258.
Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2019; 380:335–346.
Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS One 2010; 5:e10208.
Som S, Deford CC, Kaiser ML, Terrell DR, Kremer Hovinga JA, Lämmle B, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion 2012; 52:2525–2532.
Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med 2013; 368–423.
Bérangère J, Stepanian A, Hajage D, Thouzeau S, Capdenat S, Coppo P, et al. Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thromb Res 2014; 134:1074–1080.
Valsecchi C, Mirabet M, Mancini I, Biganzoli M, Schiavone L, Faraudo S, et al. Evaluation of a new, rapid, fully automated assay for the measurement of ADAMTS13 activity. ThrombHaemost 2019; 119:1767–1772.
Favresse J, Lardinois B, Chatelain B, Jacqmin H, Mullier F. Evaluation of the fully automated HemosilAcustar ADAMTS13activity assay. ThrombHaemost 2018; 118:942–944.
Stratmann J, Ward JN, Miesbach W. Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study. J Thromb Thrombolysis 2020; 50:628–631.